PCA3: What Is Its Role in Prostate Cancer Screening?

To start this activity, click Begin at the bottom of this pagePCA3: What Is Its Role in Prostate Cancer Screening?

Release Date: February 2014

Expiration Date: February 2015

Estimated time to complete the educational activity: 1 hour

This activity is jointly sponsored by Medical Education Resources and Haymarket Medical Education.

Statement of Need: PSA tests have been used extensively worldwide for screening, diagnosis, and post-treatment surveillance of prostate cancer (PCa). The universal uptake in PSA testing has led to the overdiagnosis and treatment of indolent PCa. As a result, there is a clear need for improved diagnostic and prognostic tests to indivudualize prostate cancer management.

Target Audience: This activity has been designed to meet the needs of urologists and primary-care providers who handle prostate cancer screening and diagnosis.

Educational Objectives: After completing the activity, the participant should be better able to:

  • Discuss the role of urinary biomakers for prostate cancer diagnosis.
  • Define how the PCA3 test is performed, calculated, and interpreted.
  • Review the role of the PCA3 test in relation to PSA testing, the digital rectal exam, and individual clinical judgement in an effort to reduce unnecessary biopsies.

Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Haymarket Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest: Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:

Name of Faculty Reported Financial Relationship
Reza Mehrazin, MD

Consulting Fees: Fujifilm

Marc C. Smaldone, MD, MSHP

No financial relationships to disclose


The planners of Medical Education Resources, have disclosed that they have no relevant financial relationships or conflicts of interest.

Method of Participation: There are no fees for participating in and receiving CME credit for this activity. During the period February 2014 through February 2015, participants must: 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest and submit it online. Physicians may register at www.myCME.com/renalandurologynews, and 4) complete the evaluation form online.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Page 1 of 7
Loading links....
You must be a registered member of Renal and Urology News to post a comment.